JP2010537671A5 - - Google Patents

Download PDF

Info

Publication number
JP2010537671A5
JP2010537671A5 JP2010524202A JP2010524202A JP2010537671A5 JP 2010537671 A5 JP2010537671 A5 JP 2010537671A5 JP 2010524202 A JP2010524202 A JP 2010524202A JP 2010524202 A JP2010524202 A JP 2010524202A JP 2010537671 A5 JP2010537671 A5 JP 2010537671A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
monoclonal antibody
seq
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010524202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010537671A (ja
JP5518711B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/075488 external-priority patent/WO2009033094A2/en
Publication of JP2010537671A publication Critical patent/JP2010537671A/ja
Publication of JP2010537671A5 publication Critical patent/JP2010537671A5/ja
Application granted granted Critical
Publication of JP5518711B2 publication Critical patent/JP5518711B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010524202A 2007-09-07 2008-09-05 24p4c12タンパク質に結合する抗体および関連分子 Active JP5518711B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19003407P 2007-09-07 2007-09-07
US2007077942 2007-09-07
US61/190,034 2007-09-07
USPCT/US2007/077942 2007-09-07
PCT/US2008/075488 WO2009033094A2 (en) 2007-09-07 2008-09-05 Antibodies and related molecules that bind to 24p4c12 proteins

Publications (3)

Publication Number Publication Date
JP2010537671A JP2010537671A (ja) 2010-12-09
JP2010537671A5 true JP2010537671A5 (enExample) 2011-06-16
JP5518711B2 JP5518711B2 (ja) 2014-06-11

Family

ID=40429722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524202A Active JP5518711B2 (ja) 2007-09-07 2008-09-05 24p4c12タンパク質に結合する抗体および関連分子

Country Status (9)

Country Link
EP (1) EP2185574B1 (enExample)
JP (1) JP5518711B2 (enExample)
CA (1) CA2698287A1 (enExample)
DK (1) DK2185574T3 (enExample)
ES (1) ES2424745T3 (enExample)
HR (1) HRP20130649T1 (enExample)
PL (1) PL2185574T3 (enExample)
PT (1) PT2185574E (enExample)
WO (1) WO2009033094A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244827B2 (en) * 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
WO2010022279A1 (en) * 2008-08-20 2010-02-25 Agensys, Inc. Antibodies and related molecules that bind to 58p1d12 proteins
EP2403524A4 (en) * 2009-03-06 2012-09-26 Agensys Inc CONJUGATES ANTIBODY-DRUG (ADC) BINDING PROTEINS 24P4C12
AU2012244673A1 (en) 2011-04-21 2013-11-28 Seattle Genetics, Inc. Novel binder-drug conjugates (ADCs) and their use
CN106163568B (zh) 2013-12-23 2021-03-23 拜耳制药股份公司 含纺锤体驱动蛋白(ksp)的抗体药物偶联物(adc)
CN113713091A (zh) * 2015-02-06 2021-11-30 新加坡国立大学 工程免疫细胞及其用途和生产方法
EP3310440A1 (de) 2015-06-22 2018-04-25 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ksp阻害剤および抗cd123抗体を含む特異的抗体-薬物-コンジュゲート(adc)
CN107841502A (zh) * 2016-09-17 2018-03-27 复旦大学 核酸分子ctl4hsh1、其制备方法及应用
CN107841500A (zh) * 2016-09-18 2018-03-27 复旦大学 核酸分子ctl4hsh18、其制备方法及应用
CN107841501A (zh) * 2016-09-18 2018-03-27 复旦大学 核酸分子ctl4hsh20、其制备方法及应用
CN107868783A (zh) * 2016-09-26 2018-04-03 复旦大学 核酸分子ctl4hsh2、其制备方法及应用
CN107868782A (zh) * 2016-09-26 2018-04-03 复旦大学 核酸分子ctl4hsh3、其制备方法及应用
CN107881171A (zh) * 2016-09-30 2018-04-06 复旦大学 核酸分子ctl4hsh12、其制备方法及应用
CN108070588A (zh) * 2016-11-08 2018-05-25 复旦大学 核酸分子ctl4hsh8、其制备方法及应用
CN118581046A (zh) 2016-11-22 2024-09-03 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
CN108118052A (zh) * 2016-11-29 2018-06-05 复旦大学 核酸分子ctl4hsh17、其制备方法及应用
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN108330128A (zh) * 2017-01-17 2018-07-27 复旦大学 核酸分子ctl4hsh10、其制备方法及应用
US11648269B2 (en) 2017-08-10 2023-05-16 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553079A1 (en) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
SG11202010996QA (en) 2018-05-23 2020-12-30 Nat Univ Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
WO2024192280A2 (en) * 2023-03-14 2024-09-19 Mapp Biopharmaceutical, Inc. Antibodies against orthohantaviruses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5670361A (en) 1993-05-17 1997-09-23 The Regents Of The University Of California HIV-specific ribozymes
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2303830A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
EP1171595A1 (en) * 1999-04-12 2002-01-16 Agensys, Inc. 13 transmembrane protein expressed in prostate cancer
JP2006508163A (ja) * 2002-11-27 2006-03-09 アジェンシス, インコーポレイテッド 癌の処置および検出において有用な24p4c12と称される、核酸および対応タンパク質

Similar Documents

Publication Publication Date Title
JP2010537671A5 (enExample)
US20250333533A1 (en) Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
US12059474B2 (en) Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
US12180296B2 (en) Cross species single domain antibodies targeting mesothelin for treating solid tumors
CN103068851B (zh) 内质蛋白的抗体及其用途
JP5781932B2 (ja) 腫瘍抗原の生物活性を特異的にブロックする抗体
AU2019201258A1 (en) Novel modulators and methods of use
US20180318440A1 (en) Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
JP2008546780A5 (enExample)
HRP20140171T1 (hr) Protutijela i od njih izvedene molekule koje se vežu na steap-1-proteine
AU2018250466A1 (en) Novel modulators and methods of use
JP2006204290A5 (enExample)
JP2009197002A5 (enExample)
US20080260740A1 (en) Anti-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer
RU2010116184A (ru) Новые антитела
JP2006517109A5 (enExample)
JP2006517109A (ja) アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
WO2017023780A1 (en) Antibody-drug conjugates for targeting cd56-positive tumors
JP2013538042A5 (enExample)
JP2003523207A5 (enExample)
RU2007140311A (ru) Антитела и родственные молекулы, связываюшиеся с белками 161p2f10b
US20070020278A1 (en) Diagnosing and treating cancer
CN119013305A (zh) 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物
RU2006146666A (ru) Антитела и родственные молекулы, связывающиеся с белками psca
CN119343378A (zh) 靶向itga2的抗体和包含此抗体的抗体药物缀合物